The FDA turned down a regulatory application for Probuphine, Titan Pharmaceuticals' experimental drug for opioid addiction, and asked the firm to submit additional data on the drug's efficacy. Probuphine is a long-acting version of buprenorphine, which is being marketed as Subutex and Suboxone. Titan said it was "extremely surprised and disappointed."

Full Story:

Related Summaries